Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17991524 | 1.00 | HDAC6 (0.38) | HDAC6HDAC8HDAC1HDAC3MEN1 | |
| SCHEMBL17991561 | 0.89 | HDAC6 (0.41) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL17991522 | 0.86 | RAB9A (0.40) | HDAC6HDAC8HDAC1KMT2ATSHR | |
| SCHEMBL29501153 | 0.86 | RAB9A (0.40) | HDAC6HDAC8HDAC1KMT2ATSHR | |
| SCHEMBL17960578 | 0.86 | HDAC6 (0.40) | HDAC6HDAC8HDAC1HDAC3MEN1 | |
| SCHEMBL17960577 | 0.86 | HDAC6 (0.40) | HDAC6HDAC8HDAC1HDAC3MEN1 | |
| SCHEMBL17960283 | 0.84 | HDAC6 (0.42) | HDAC6HDAC8HDAC1HDAC3KMT2A | |
| SCHEMBL17960405 | 0.84 | HDAC6 (0.42) | HDAC6HDAC8HDAC1HDAC3KMT2A | |
| SCHEMBL17957528 | 0.84 | HDAC6 (0.42) | HDAC6HDAC8HDAC1HDAC3KMT2A | |
| SCHEMBL17957525 | 0.84 | HDAC6 (0.42) | HDAC6HDAC8HDAC1HDAC3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279681-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279681-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HDAC6 7/4885HDAC8 9/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.